New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib

por Cowey, C Lance, Sonpavde, Guru, Hutson, Thomas E
Publicado 2010

Salen Promoted Enantioselective Nazarov Cyclizations of Activated and Unactivated Dienones

por Hutson, Gerri E., Türkmen, Yunus E., Rawal, Viresh H.
Publicado 2013

New treatment options for metastatic renal cell carcinoma

por Rodriguez-Vida, Alejo, Hutson, Thomas E, Bellmunt, Joaquim, Strijbos, Michiel H
Publicado 2017

Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line the...

por Hutson, Thomas E, Liu, Frank X, Dieyi, Christopher, Kim, Ruth, Krulewicz, Stan, Kasturi, Vijay, Bhanegaonkar, Abhijeet
Publicado 2021

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α

por Patil, S, Figlin, R A, Hutson, T E, Michaelson, M D, Negrier, S, Kim, S T, Huang, X, Motzer, R J
Publicado 2012

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis

por Procopio, G, Bellmunt, J, Dutcher, J, Bracarda, S, Knox, J, Brueckner, A, Molnar, I, Escudier, B, Hutson, T E
Publicado 2013

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study

por Molina, Ana M., Hutson, Thomas E., Nosov, Dmitry, Tomczak, Piotr, Lipatov, Oleg, Sternberg, Cora N., Motzer, Robert, Eisen, Tim
Publicado 2018

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

por Molina, Ana M., Hutson, Thomas E., Larkin, James, Gold, Anne M., Wood, Karen, Carter, Dave, Motzer, Robert, Michaelson, M. Dror
Publicado 2013

Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab

por Motzer, Robert, George, Saby, Merchan, Jaime R, Hutson, Thomas E, Song, Xun, Perini, Rodolfo F, Xie, Ran, Bapat, Urmi, Puente, Javier
Publicado 2023

Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal

por Chapman, Scott A, Irwin, Eric D, Abou-Karam, Nada M, Rupnow, Nichole M, Hutson, Katherine E, Vespa, Jeffrey, Roach, Robert M
Publicado 2014

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

por Suttle, A B, Ball, H A, Molimard, M, Hutson, T E, Carpenter, C, Rajagopalan, D, Lin, Y, Swann, S, Amado, R, Pandite, L
Publicado 2014

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

por Suttle, A B, Ball, H A, Molimard, M, Hutson, T E, Carpenter, C, Rajagopalan, D, Lin, Y, Swann, S, Amado, R, Pandite, L
Publicado 2014

Sequential Therapy in Metastatic Renal Cell Carcinoma

por Hirsch, Bradford R., Burke, John M., Agrawal, Manish, Hauke, Ralph J., Hutson, Thomas E., Doshi, Gury, Fleming, Mark T., Vogelzang, Nicholas J.
Publicado 2016

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis

por Bracarda, S, Hutson, T E, Porta, C, Figlin, R A, Calvo, E, Grünwald, V, Ravaud, A, Motzer, R, Kim, D, Anak, O, Panneerselvam, A, Escudier, B
Publicado 2012

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

por Motzer, R J, Escudier, B, Bukowski, R, Rini, B I, Hutson, T E, Barrios, C H, Lin, X, Fly, K, Matczak, E, Gore, M E
Publicado 2013

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3

por Meza, Luis, McDermott, David F, Escudier, Bernard, Hutson, Thomas E, Porta, Camillo, Verzoni, Elena, Atkins, Michael B, Kasturi, Vijay, Pal, Sumanta K, Rini, Brian
Publicado 2022

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy...

por Motzer, Robert J., Hutson, Thomas E., Hudes, Gary R., Figlin, Robert A., Martini, Jean-Francois, English, Patricia A., Huang, Xin, Valota, Olga, Williams, J. Andrew
Publicado 2014

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma

por Zurita, A J, Gagnon, R C, Liu, Y, Tran, H T, Figlin, R A, Hutson, T E, D'Amelio Jr, A M, Sternberg, C N, Pandite, L N, Heymach, J V
Publicado 2017

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma

por Sternberg, Cora N., Motzer, Robert J., Hutson, Thomas E., Choueiri, Toni K., Kollmannsberger, Christian, Bjarnason, Georg A., Nathan, Paul, Porta, Camillo, Grünwald, Viktor, Dezzani, Luca, Han, Jackie, Tannir, Nizar M.
Publicado 2019

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

por Harmon, Charles S., DePrimo, Samuel E., Figlin, Robert A., Hudes, Gary R., Hutson, Thomas E., Michaelson, M. Dror, Négrier, Sylvie, Kim, Sindy T., Huang, Xin, Williams, J. Andrew, Eisen, Tim, Motzer, Robert J.
Publicado 2013